A phase 2 clinical trial of a drug that may alleviate brain swelling – a dangerous stroke complication – suggests the treatment may help reduce brain injury and death, and information from the study will help design the phase 3 trial.
Departments, Centers, & Programs:
Neuroscience Intensive Care Unit
55 Fruit Street
Boston, MA 02114-2696
15 Parkman Street
Boston, MA 02114-3117
- MD, PhD, Harvard Medical School
- Residency, Brigham and Women's Hospital
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Neurology, American Board of Psychiatry and Neurology
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Kimberly's laboratory is devoted to the study of secondary brain injury after stroke. His research group (Kimberly Lab) develops novel tools, including neuroimaging analysis, metabolomics and proteomics, to identify clinically relevant markers of stroke. Promising candidates may become diagnostic or prognostic biomarkers. However, the primary goal of the laboratory is to leverage biomarkers to study the biological and pathological events following acute brain injury and to bring new treatments to patients through multicenter clinical trials.